Sickle cell anemia in the female patient

Obstetrical and Gynecological Survey

Volumn 61, Issue 5, 2006, Pages 343-352

  Dauphin McKenzie, Nathalie ^a,d   Gilles, Jerry M ^b   Jacques, Elvire ^b   Harrington, Thomas ^c  

^a JACKSON MEMORIAL HOSPITAL   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,2 BIS(4 FLUOROPHENYL) 2 PHENYLACETAMIDE; 5 AZA 2' DEOXYCYTIDINE; ANTIOXIDANT; ASCORBIC ACID; BUTYRIC ACID; CALCIUM CHANNEL BLOCKING AGENT; CLOTRIMAZOLE; DEFEROXAMINE; GESTAGEN; HEMOGLOBIN F; HEMOGLOBIN S; HYDROXYUREA; IRON CHELATING AGENT; MAGNESIUM; MEDROXYPROGESTERONE ACETATE; NARCOTIC ANALGESIC AGENT; NITRIC OXIDE; NOMEGESTROL ACETATE; OPIATE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE;

ASCORBIC ACID DEFICIENCY; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CONTINUING EDUCATION; CONTRACEPTION; DISEASE SEVERITY; DRUG IMPLANT; ERYTHROCYTE MEMBRANE; EXCHANGE BLOOD TRANSFUSION; FAMILY PLANNING; FEMALE; GENETIC COUNSELING; HEMOSIDEROSIS; HUMAN; LABORATORY TEST; LIFE EXPECTANCY; PAIN; PATHOPHYSIOLOGY; PREECLAMPSIA; PREGNANCY; PRENATAL CARE; REVIEW; RISK BENEFIT ANALYSIS; SICKLE CELL ANEMIA; SMALL FOR DATE INFANT; SYMPTOMATOLOGY;

ANEMIA, SICKLE CELL; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC;

EID: 33646771775     PISSN: 00297828     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ogx.0000216976.15100.29     Document Type: Review

References (42)

1. Ashley-Koch A, Yang Q, Olney RS. Hemoglobin S allele and sickle cell disease. Am J Epidemiol 2000;151:839-845.
2. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994;330:1639-1644.
3. Gaston M, Rosse WF. The cooperative study of sickle cell disease: review of study design and objectives. Am J Pediatr Hematol Oncol 1982;4:197-201.
4. Mohanty D, Mukherjee MB. Sickle cell disease in India. Curr Opin Hematol 2002;9:117-122.
5. Dash BP, Das RK. Age, sex and seasonal variations of sickle cell disorder cases in Orissa. J Hum Ecol 1998;9:281-284.
6. Nagel RL. Pleiotropic and epistatic effects in sickle cell anemia. Curr Opin Hematol 2001;8:105-110.
7. Kaul DK, Fabry ME, Nagel RL, et al. Pathophysiology of vascular obstruction in sickle cell syndromes. Blood Rev 1996;10:29-44.
8. Mahaseth H, Vercellotti GM, Welch TE, et al. Polynitroxyl albumin inhibits inflammation and vasoocclusion in transgenic sickle mice. J Lab Clin Med 2005;145:205-211.
9. Wilgenbus K, Lichter P. DNA. chip technology. J Mol Med 1999;77:761-768.
10. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle-cell anemia and abnormal results on transcranial doppler ultrasonography. N Engl J Med 1998;339:5.
11. Miller ST, Sleeper LA, Pegelow CH, et al. Prediction of adverse outcomes in children with sickle-cell disease. N Engl J Med 2000;342:83.
12. Alexander N, Higgs D, Dover G, et al. Are there clinical phenotypes of homozygous sickle cell disease? Br J Haematol 2004;126:606-611.
13. Poddar D, Maude GH, Plant MJ, et al. Pregnancy in Jamaican women with homozygous sickle cell disease: fetal and maternal outcome. BJOG 1986;93:927.
14. Powars DR, Sandhu M, Niland-Weiss J, et al. Pregnancy in sickle cell disease. Obstet Gynecol 1986;67:217.
15. Smith JA, Espeland M, Bellevue R, et al. Pregnancy in sickle cell disease: experience of the Cooperative Study of Sickle Cell Disease. Obstet Gynecol 1996;87:199.
16. Cunningham FG, Hauth JC, Leveno KJ, et al. Williams' Obstetrics. Stamford, CT: McGraw-Hill Companies, Inc, 2005.
17. Van Erk A, Visschers G, Jansen W, et al. Maternal death due to sickle cell chronic lung disease. Am J Obstet Gynecol 1992;99:162-163.
18. Veille J, Hanson R. Left ventricular systolic and diastolic function in pregnant patients with sickle cell disease. Am J Obstet Gynecol 1994;170:107-110.
19. Claster S, Vichinsky EP. Managing sickle cell disease. BMJ 2003;327:1151-1155.
20. National Institutes of Health, National Heart, Lung, and Blood Institute, and Division of Blood Diseases and Resources. The Management of Sickle Cell Disease. Bethesda, MD: National Institutes of Health, NIH Publication No. 02-2117.
21. Vichinsky EP. Comprehensive care in sickle cell disease: its impact on morbidity and mortality. Semin Hematol 1991;28:220-226.
22. Johnson CS, Omata M, Tong MJ, et al. Liver involvement in sickle cell disease. Medicine 1985;64:349-356.
23. Schmalzer EA, Lee JO, Brown AK, et al. Viscosity of mixtures of sickle cells and normal red cells at varying hematocrit levels: implications for transfusion. Transfusion 1987:228-233.
24. Adams RJ, Mackie VC, Bramilla D, et al. Stroke prevention trial in sickle cell anemia. Control Clin Trials 1998;19:110-129.
25. Moser FG, Miller ST, Bello JA, et al. The spectrum of brain MR abnormalities in sickle-cell disease: a report from the Cooperative Study of Sickle Cell Disease. AJNR Am J Neuroradiol 1996;17:965-972.
26. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998;339:5-11.
27. Styles LA, Vichinsky EP. Core decompression in avascular necrosis of the hip in sickle-cell disease. Am J Hematol 1996;52:103-107.
28. Abbott KC, Hypolite IO, Agodoa LY. Sickle cell nephropathy at end-stage renal disease in the United States: patient characteristics and survival. Clin Nephrol 2002;58:9-15.
29. Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med 2000;342:1855-1865.
30. Vichinsky EP. New therapies in sickle cell disease. Lancet 2002;360:629-631.
31. Morris CR. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Blood 2000;6(suppl, part 1):485a.
32. Gladwin M, Sachdev V, Jison M, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004;350:886-895.
33. Vichinsky E, ed. Transfusion-Related Iron Overload in Sickle Cell Anemia. Philadelphia: Harcourt Health Sciences. Young NS, Beris P, eds. Semin Hematol 38(suppl 1):1-5, 14-23.
34. Koshy M, Burd L, Wallace D, et al. Prophylactic red-cell transfusions in pregnant patients with sickle cell disease: a randomized cooperative study. N Engl J Med 1988;319:1447.
35. Brittenham GM, Cohen AR, McLaren CE, et al. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol 1993;42:81-85.
36. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med 1991;325:11-16.
37. Charache S, Terrin ML, Moore RD, et al., the Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 1995;332:1317.
38. Morris CR, Kuypers FA, Larkin S, et al. Arginine therapy: a novel strategy to induce nitric oxide production in sickle cell disease. Br J Haematol 2000;111:498-500.
39. Goldberg M, Brugnara C, Dover G, et al. Treatment of sickle cell anemia with hydroxyurea and erythropoietin. N Engl J Med 1990;323:366-372.
40. Halsey C, Roberts IA, et al. The role of hydroxyurea in sickle cell disease. Br J Haematol 2003;120:177-186.
41. Walters MC, Storb R, Patience M, et al. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. Blood 2000;95:1918-2924.
42. de Abood M, de Castillo Z, Guerrero F, et al. Effect of Depo-Provera or Microgynon on the painful crises of sickle cell anemia patients. Contraception 1997;56:313.